Core Concepts
Methotrexate is a valuable treatment option for pediatric inflammatory skin diseases, with specific dosing and monitoring recommendations.
Abstract
The article discusses the guidelines for using methotrexate (MTX) in pediatric patients with inflammatory skin diseases. Key points include dosing recommendations, the onset of efficacy, and monitoring needs. The guidelines were developed by a committee of experts and published in Pediatric Dermatology. Dr. Elaine C. Siegfried, a project cochair, emphasizes the importance of MTX as a cost-effective and well-tolerated treatment option. The guidelines address the lack of FDA-approved indications for MTX in pediatric inflammatory skin diseases and provide recommendations for indications, dosing, adverse effects, and monitoring.
Highlights:
- Maximum dose of MTX for pediatric patients is 1 mg/kg, not to exceed 25 mg/week.
- Test doses are not necessary for low-dose MTX initiation.
- Onset of efficacy with MTX may take 8-16 weeks.
- Guidelines developed by a committee of 23 experts.
- MTX is classified as an immune modulator.
- Recommendations cover indications, dosing, adverse effects, and monitoring needs.
Stats
"the maximum dose is considered to be 1 mg/kg and not to exceed 25 mg/week"
"the onset of efficacy with MTX may take 8-16 weeks"
"Food and Drug Administration labeling does not include approved indications for the use of MTX for many inflammatory skin diseases in pediatric patients"
Quotes
"Methotrexate is a cost-effective, readily accessible, well-tolerated, useful, and time-honored option for children with a spectrum of inflammatory skin diseases." - Dr. Elaine C. Siegfried